Leerink Swann Begins Coverage on Satsuma Pharmaceuticals (NASDAQ:STSA)

Share on StockTwits

Leerink Swann began coverage on shares of Satsuma Pharmaceuticals (NASDAQ:STSA) in a research report released on Tuesday, The Fly reports. The firm issued an outperform rating and a $20.00 price objective on the financial services provider’s stock.

STSA has been the subject of several other reports. Svb Leerink assumed coverage on Satsuma Pharmaceuticals in a research report on Tuesday. They set an outperform rating for the company. Credit Suisse Group assumed coverage on Satsuma Pharmaceuticals in a research report on Tuesday. They set an outperform rating and a $16.00 price objective for the company.

Shares of STSA stock opened at $9.73 on Tuesday. Satsuma Pharmaceuticals has a twelve month low of $9.02 and a twelve month high of $19.90.

In other news, major shareholder Group Holdings (Sbs) Advis Tpg bought 100,000 shares of the company’s stock in a transaction on Tuesday, September 17th. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $1,500,000.00. Also, Director Rajeev M. Shah bought 1,333,333 shares of the company’s stock in a transaction on Tuesday, September 17th. The stock was purchased at an average price of $15.00 per share, with a total value of $19,999,995.00. Insiders acquired 1,434,333 shares of company stock valued at $21,503,805 over the last quarter. Corporate insiders own 45.65% of the company’s stock.

About Satsuma Pharmaceuticals

Satsuma Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled single-use nasal delivery device.

See Also: Penny Stocks, Risk and Reward Factors

The Fly

Receive News & Ratings for Satsuma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Satsuma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.